carmustine has been researched along with Acute Lymphoid Leukemia in 16 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The distribution of adverse prognostic factors was comparable in the two-induction arm." | 2.70 | Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study. ( Bernard, M; Casassus, P; Delain, M; Desablens, B; Guilhot, F; Hunault-Berger, M; Ifrah, N; Jouet, JP; Milpied, N; Sadoun, A, 2001) |
| "Fifty-six patients with non-Hodgkin's lymphoma (NHL, n = 26), Hodgkin's disease (HD, n = 17), or acute lymphoblastic leukemia (ALL, n = 13) with a history of previous radiation therapy were treated with cyclophosphamide (7." | 2.68 | High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. ( Anasetti, C; Bensinger, WI; Buckner, CD; Clift, RA; Demirer, T; Lilleby, K; Martin, P; Petersen, FB; Sanders, J; Weaver, CH, 1995) |
| "Etoposide has also been tested in a wide range of combination regimens, but for many of these combinations, relatively few patients are included, and some combinations have only been tested in patients who have undergone autologous transplants." | 2.48 | High-dose etoposide in allogeneic stem cell transplantation. ( Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH, 2012) |
| "Cotreatment with methoxyamine, a base excision repair inhibitor, did not sensitize CEM-R cells to TMZ, suggesting little or no contribution of N-alkylation to TMZ-induced cytotoxicity." | 1.35 | Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance. ( Ogawa, M; Ueda, T; Yamauchi, T, 2008) |
| " Adverse prognostic factors for failure-free survival include high LDH at the time of autologous BMT, chemotherapy-refractory disease and multiple prior relapses." | 1.29 | High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. ( Andersson, B; Dimopoulos, M; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Rodriguez, M; Suki, S; Tabocoff, J; van Besien, K, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 8 (50.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, CR | 1 |
| Kang, HJ | 1 |
| Park, KD | 1 |
| Shin, HY | 1 |
| Ahn, HS | 1 |
| Bruserud, O | 1 |
| Reikvam, H | 1 |
| Kittang, AO | 1 |
| Ahmed, AB | 1 |
| Tvedt, TH | 1 |
| Sjo, M | 1 |
| Hatfield, KJ | 1 |
| Rivero-Garvía, M | 1 |
| Márquez-Rivas, J | 1 |
| Rivas, E | 1 |
| Medina-López, D | 1 |
| Quiroga-Cantero, E | 1 |
| Mielke, S | 1 |
| Potthoff, K | 1 |
| Feuerhake, F | 1 |
| Bley, TA | 1 |
| Windfuhr, M | 1 |
| Bertz, H | 1 |
| Finke, J | 1 |
| Yamauchi, T | 1 |
| Ogawa, M | 1 |
| Ueda, T | 1 |
| Jost, LM | 1 |
| Jacky, E | 1 |
| Dommann-Scherrer, C | 1 |
| Honegger, HP | 1 |
| Maurer, R | 1 |
| Sauter, C | 1 |
| Stahel, RA | 1 |
| Scheid, C | 1 |
| Pettengell, R | 1 |
| Ghielmini, M | 1 |
| Radford, JA | 1 |
| Morgenstern, GR | 1 |
| Stern, PL | 1 |
| Crowther, D | 1 |
| van Besien, K | 1 |
| Tabocoff, J | 1 |
| Rodriguez, M | 1 |
| Andersson, B | 1 |
| Mehra, R | 1 |
| Przepiorka, D | 1 |
| Dimopoulos, M | 1 |
| Giralt, S | 1 |
| Suki, S | 1 |
| Khouri, I | 1 |
| Demirer, T | 1 |
| Weaver, CH | 2 |
| Buckner, CD | 1 |
| Petersen, FB | 2 |
| Bensinger, WI | 1 |
| Sanders, J | 1 |
| Clift, RA | 1 |
| Lilleby, K | 1 |
| Anasetti, C | 2 |
| Martin, P | 2 |
| Appelbaum, FR | 1 |
| Clift, R | 1 |
| Singer, J | 1 |
| Press, O | 1 |
| Bensinger, W | 1 |
| Bianco, J | 1 |
| Weiss, M | 1 |
| Hunault-Berger, M | 1 |
| Milpied, N | 1 |
| Bernard, M | 1 |
| Jouet, JP | 1 |
| Delain, M | 1 |
| Desablens, B | 1 |
| Sadoun, A | 1 |
| Guilhot, F | 1 |
| Casassus, P | 1 |
| Ifrah, N | 1 |
| Kantarjian, HM | 1 |
| Walters, RS | 1 |
| Keating, MJ | 1 |
| Smith, TL | 1 |
| O'Brien, S | 1 |
| Estey, EH | 1 |
| Huh, YO | 1 |
| Spinolo, J | 1 |
| Dicke, K | 1 |
| Barlogie, B | 1 |
| Ribera, JM | 1 |
| Grañena, A | 1 |
| Rozman, C | 1 |
| Urbano-Ispizua, A | 1 |
| Bladé, J | 1 |
| Carreras, E | 1 |
| Cervantes, F | 1 |
| Marín, P | 1 |
| Sierra, J | 1 |
| Nomdedeu, B | 1 |
| Spinolo, JA | 1 |
| Dicke, KA | 1 |
| Horwitz, LJ | 1 |
| Jagannath, S | 1 |
| McCredie, K | 1 |
| Estey, E | 1 |
| Kantarjian, H | 1 |
| Zander, AR | 1 |
| Keating, M | 1 |
| Spitzer, G | 1 |
| Kolb, HJ | 1 |
| Bender-Götze, C | 1 |
| Haas, RJ | 1 |
| Holler, E | 1 |
| Thierfelder, S | 1 |
| Wilmanns, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612] | 50 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
| PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia[NCT00494897] | Phase 4 | 374 participants (Actual) | Interventional | 1996-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carmustine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
High-dose etoposide in allogeneic stem cell transplantation.
Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chem | 2012 |
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials | 2001 |
6 trials available for carmustine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1995 |
High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1990 |
[Adult acute lymphoblastic leukemia: preliminary results of the LAL-86 protocol].
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; | 1990 |
Bone marrow transplantation for the treatment of leukaemia-results of the Munich Cooperative Group.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cyclophosphamid | 1989 |
8 other studies available for carmustine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
High-dose chemotherapy and autologous peripheral blood stem cell transplantation with BCVAC regimen followed by maintenance chemotherapy for children with very high risk acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Child; Child, Preschool; Com | 2018 |
Primary cerebral radiotherapy-induced rhabdomyosarcoma: treatment with intraoperative carmustine implants.
Topics: Brain Neoplasms; Carmustine; Child; Female; Humans; Intraoperative Period; Neoplasms, Radiation-Indu | 2013 |
Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality | 2007 |
Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadmiu | 2008 |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; | 1995 |
High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1995 |
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1993 |
High-dose chemotherapy and unpurged autologous bone marrow transplantation for acute leukemia in second or subsequent remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1990 |